Cytosorbents Corporation
CTSO
$1.10
-$0.06-5.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 14.51% | -12.40% | -12.31% | -11.36% | -10.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.51% | -12.40% | -12.31% | -11.36% | -10.39% |
| Cost of Revenue | 14.64% | -35.03% | -46.26% | -46.70% | -34.57% |
| Gross Profit | 14.45% | 1.71% | 12.97% | 16.66% | 5.89% |
| SG&A Expenses | -8.96% | 3.21% | 5.81% | 7.37% | 4.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.07% | -14.34% | -12.42% | -9.18% | -4.01% |
| Operating Income | 47.59% | 16.94% | 12.55% | 6.73% | -3.08% |
| Income Before Tax | 25.45% | 17.56% | 1.66% | 9.83% | 11.34% |
| Income Tax Expenses | -107.79% | 25.53% | 25.53% | 25.53% | 25.53% |
| Earnings from Continuing Operations | 29.16% | 17.19% | 0.67% | 9.28% | 10.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.16% | 17.19% | 0.67% | 9.28% | 10.87% |
| EBIT | 47.59% | 16.94% | 12.55% | 6.73% | -3.08% |
| EBITDA | 50.22% | 18.83% | 14.79% | 9.15% | -1.27% |
| EPS Basic | 41.99% | 29.06% | 10.41% | 15.30% | 12.93% |
| Normalized Basic EPS | 39.23% | 26.86% | 10.04% | 14.18% | 11.91% |
| EPS Diluted | 41.99% | 29.06% | 10.41% | 15.30% | 13.37% |
| Normalized Diluted EPS | 39.23% | 26.86% | 10.04% | 14.18% | 11.91% |
| Average Basic Shares Outstanding | 21.90% | 19.28% | 14.04% | 8.44% | 2.48% |
| Average Diluted Shares Outstanding | 21.90% | 19.28% | 14.04% | 8.44% | 2.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |